Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght, shared a post on X:
“In this Healthcare Unfiltered Express HUExpress, Amer Zeidan of Smilow Cancer Hospital joins me to discuss the recent VERONA trial in high-risk MDS and the negative results publicized. What is next for HR-MDS?”
More posts featuring Chadi Nabhan on OncoDaily.